Melanoma & Skin Cancer | Specialty

The melanoma & skin cancer condition center is a comprehensive resource for clinical news and expert insights on melanoma & skin cancer. Read more at OncLive.

Neoadjuvant Darovasertib Receives FDA Breakthrough Therapy Designation for Uveal Melanoma

April 3rd 2025

Updated interim phase 2 data showed the clinical efficacy and safety of neoadjuvant darovasertib monotherapy in localized uveal melanoma.

Silmitasertib Drives Disease Control in Advanced Basal Cell Carcinoma

April 2nd 2025

Silmitasertib generated disease control in patients with locally advanced or metastatic basal cell carcinoma.

Neoadjuvant Pembrolizumab Is Safe and Effective in Resectable Stage III/IV Melanoma

March 30th 2025

Single-dose neoadjuvant pembrolizumab was safe with no surgical delays and boosted MPR rates in resectable melanoma.

New Drug Therapy Combination Shows Promise For Advanced Melanoma Patients

March 28th 2025

A federally funded research team is testing a new combination drug therapy that could both treat and prevent melanoma metastasis to the brain.

Moffitt Study Finds New Immunotherapy Strategy for Enhancing Melanoma Treatment

March 24th 2025

Moffitt Cancer Center researchers found a way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure.

D-MNA Displays Potential as Noninvasive Therapy in Basal Cell Carcinoma of the Skin

March 14th 2025

Micro-array needles containing doxorubicin displayed safety and early activity in basal cell carcinoma of the skin.

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

March 11th 2025

MT-8421, a novel engineered toxin body targeting CTLA-4, was not associated with grade 4 or 5 toxicities in patients with select advanced solid tumors.

Five Under 5: Top Oncology Videos for the Week of 2/23

March 2nd 2025

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

Immunotherapy Combinations Reign Supreme in Upfront Melanoma Management

February 28th 2025

Teresa Petrella, MD, MHSc, FRCPC, discusses long-term data that inform the sequencing of immunotherapy and targeted therapies for frontline melanoma.

Dr Patel on the Potential for Adjuvant Immunotherapy in CSCC

February 24th 2025

Sapna Patel, MD, discusses the potential for adjuvant immunotherapy in patients with high-risk cutaneous squamous cell carcinoma.

The OncFive: Top Oncology Articles for the Week of 2/16

February 22nd 2025

FDA grants priority review to zongertinib in HER2-mutant NSCLC and dordaviprone for recurrent H3K27M+ diffuse glioma, and more from OncLive this week.

Updated NCCN Guidelines Recommend HEPZATO KIT for Hepatic-Dominant Uveal Melanoma

February 19th 2025

The NCCN Guidelines for metastatic uveal melanoma now recommend HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant disease.

Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma

February 18th 2025

Tara C. Mitchell, MD, discusses considerations and lingering questions regarding pre- and post-operative management strategies in stage IIB/IIIC melanoma.

Five Under 5: Top Oncology Videos for the Week of 2/9

February 16th 2025

The top 5 videos of the week cover insights in plexiform neurofibromas, melanoma, myeloma, leukemia, and LBCL.

The OncFive: Top Oncology Articles for the Week of 2/9

February 15th 2025

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

Nivolumab Plus Relatlimab Fails to Improve RFS in Resected Stage III/IV Melanoma

February 14th 2025

Nivolumab plus relatlimab did not improve recurrence-free survival vs nivolumab in resected stage III/IV melanoma.

Dr Petrella on Selecting Frontline Therapy in Metastatic Melanoma

February 12th 2025

Teresa Petrella, MD, MHSc, FRCPC, discusses considerations in selecting frontline therapy for patients with metastatic melanoma.

NCCN Updates ctDNA Stance in Colon, Rectal, and MCC Guidelines

February 12th 2025

The NCCN guidelines have been updated to specify the standing of ctDNA as a biomarker in colon and rectal cancer, as well as in MCC.

Dr Hamid on the Potential for Cancer Vaccines in Melanoma

February 12th 2025

Omid Hamid, MD, provides insight on the potential role of cancer vaccines in melanoma.

Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma

February 11th 2025

Marlana M. Orloff, MD, discusses optimal therapeutic approaches for patients with uveal melanoma that is rapidly progressing.